BiondVax Pharmaceuticals Ltd (BVXV)

[TechKim]

In connection with the previous announcement made by BiondVax Pharmaceuticals Ltd. (“BiondVax” or the “Company”) on the Company’s intention to delist its ordinary shares, NIS 0.0000001 par value each (the “Shares”) solely from the Tel Aviv Stock Exchange Ltd. (“TASE”), the Company hereby updates the following:

The Shares will be delisted from the TASE on January 22, 2018 (“Delisting Date”). The last trading date on TASE will be January 18, 2018. The Company’s American Depositary Shares (“ADSs”), each representing forty (40) of our Shares, shall continue to be traded on the Nasdaq Capital Market (the “Nasdaq”).

Until Delisting Date, BiondVax’s Shares will continue to be traded on the TASE. Shareholders who are interested in continuing to hold or trade the Company’s Shares on the Nasdaq should notify their bank or broker and request to convert their Shares to ADSs. The Company will bear the cost and commissions associated with the conversion of the Shares to ADSs charged by the banks and brokers until January 22, 2018. Every forty (40) Shares shall be converted to one (1) ADS.

The Company urges all holders of Shares that are traded on the TASE to convert their Shares at the earliest.